Druggable fusion events were identified in 7.1% (5/70) of tumor specimens: FGFR3-TACC3 (n = 2), NTRK2 fusions (n = 1), ALK (n = 1), and ROS1 (n = 1). This evidence concerns the gene TACC3 and neoplasm.